This Article Full Text Full Text (PDF) All Versions of this Article: 111/24/3296    most recent CIRCULATIONAHA.104.473165v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rajamannan, N. M. Articles by Spelsberg, T. C. Search for Related Content PubMed PubMed Citation Articles by Rajamannan, N. M. Articles by Spelsberg, T. C. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Heart Valve Diseases Related Collections Smooth muscle proliferation and differentiation Valvular heart disease CV surgery: valvular disease Other Research

(Circulation. 2005;111:3296-3301.)
© 2005 American Heart Association, Inc.

Valvular Heart Disease

Calcified Rheumatic Valve Neoangiogenesis Is Associated With Vascular Endothelial Growth Factor Expression and Osteoblast-Like Bone Formation

Nalini M. Rajamannan, MD; Thomas B. Nealis, BSc; Malayannan Subramaniam, PhD; Sanjay Pandya, MD; Stuart R. Stock, PhD; Constatine I. Ignatiev, PhD; Thomas J. Sebo, MD, PhD; Todd K. Rosengart, MD; William D. Edwards, MD; Patrick M. McCarthy, MD; Robert O. Bonow, MD; Thomas C. Spelsberg, PhD

From the Divisions of Cardiology and Cardiothoracic Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Ill (N.M.R., T.B.N., S.P., P.M.M., R.O.B.); Departments of Molecular Biology and Biochemistry (M.S., T.C.S.) and Laboratory Medicine and Pathology (T.J.S., W.D.E.), Mayo Clinic, Rochester, Minn; Institute for Bioengineering and Nanoscience in Advanced Medicine, Northwestern University, Chicago, Ill (S.R.S., C.I.I.); Cardiology and Cardiothoracic Surgery, Northwestern Evanston Healthcare, Chicago, Ill (T.K.R.).

Correspondence to Nalini M. Rajamannan, MD, Northwestern University, Feinberg School of Medicine, 303 E Chicago, Tarry 12-717, Chicago, IL 60611. E-mail n-rajamannan{at}northwestern.edu

Received May 5, 2004; revision received February 9, 2005; accepted February 16, 2005.

Background— Rheumatic heart disease is the most common cause of valvular disease in developing countries. Despite the high prevalence of this disease, the cellular mechanisms are not well known. We hypothesized that rheumatic valve calcification is associated with an osteoblast bone formation and neoangiogenesis.

Methods and Results— To test this hypothesis, we examined human rheumatic valves replaced at surgery (n=23), normal human valves (n=20) removed at cardiac transplantation, and degenerative mitral valve leaflets removed during surgical valve repair (n=15). Microcomputed tomography was used to assess mineralization fronts to reconstruct the extents of mineralization. Immunohistochemistry was used to localize osteopontin protein, -actin, osteocalcin, vascular endothelial growth factor, von Willebrand factor, and CD68 (human macrophage). Microcomputed tomography demonstrated complex calcification developing within the heavily calcified rheumatic valves, not in the degenerative mitral valves and control valves. Immunohistochemistry localized osteopontin and osteocalcin to areas of smooth muscle cells within microvessels and proliferating myofibroblasts. Vascular endothelial growth factor was present in areas of inflammation and colocalized with the CD68 stain primarily in the calcified rheumatic valves. Alizarin red, osteopontin, and osteocalcin protein expression was upregulated in the calcified rheumatic valves and was present at low levels in the degenerative mitral valves.

Conclusions— These findings support the concept that rheumatic valve calcification is not a random passive process but a regulated, inflammatory cellular process associated with the expression of osteoblast markers and neoangiogenesis.

Key Words: angiogenesis • calcification • cardiovascular diseases • rheumatic heart disease • valves

This article has been cited by other articles:

				O. Ben-Yehuda and A. N. DeMaria Statins in Rheumatic Heart Disease: Taking the Bite Out? J. Am. Coll. Cardiol., May 19, 2009; 53(20): 1880 - 1882. [Full Text] [PDF]

				A. Parolari, C. Loardi, L. Mussoni, L. Cavallotti, M. Camera, P. Biglioli, E. Tremoli, and F. Alamanni Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention Eur. J. Cardiothorac. Surg., March 1, 2009; 35(3): 493 - 504. [Abstract] [Full Text] [PDF]

				X. Yang, D. A. Fullerton, X. Su, L. Ao, J. C. Cleveland Jr, and X. Meng Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J. Am. Coll. Cardiol., February 10, 2009; 53(6): 491 - 500. [Abstract] [Full Text] [PDF]

				A. B. Rossebo, T. R. Pedersen, K. Boman, P. Brudi, J. B. Chambers, K. Egstrup, E. Gerdts, C. Gohlke-Barwolf, I. Holme, Y. A. Kesaniemi, et al. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis N. Engl. J. Med., September 25, 2008; 359(13): 1343 - 1356. [Abstract] [Full Text] [PDF]

				K. D. O'Brien Pathogenesis of Calcific Aortic Valve Disease: A Disease Process Comes of Age (and a Good Deal More) Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1721 - 1728. [Abstract] [Full Text] [PDF]

				S. H. Rahimtoola The Year in Valvular Heart Disease J. Am. Coll. Cardiol., January 17, 2006; 47(2): 427 - 439. [Full Text] [PDF]